High sequence-coverage detection of proteolytic peptides using a bis(terpyridine)ruthenium(II) complex by Ito, Akihiro et al.
Osaka University
Title High sequence-coverage detection of proteolytic peptides usinga bis(terpyridine)ruthenium(II) complex
Author(s)
Ito, Akihiro; Okamura, Taka-aki; Masui, Ken; Kaneko, Maki;
Masui, Ryoji; Ake, Kojiro; Kuramitsu, Seiki; Yamaguchi,
Minoru; Kuyama, Hiroki; Ando, Eiji; Norioka, Shigemi;
Nakazawa, Takashi; Tsunasawa, Susumu; Yamamoto, Hitoshi;
Ueyama, Norikazu
CitationANALYST. 132(4) P.358-P.364
Issue Date2007
Text Versionpublisher
URL http://hdl.handle.net/11094/3452
DOI 10.1039/b610284k
Rights
Osaka University
High sequence-coverage detection of proteolytic peptides using a
bis(terpyridine)ruthenium(II) complex{
Akihiro Ito,a Taka-aki Okamura,*a Ken Masui,a Maki Kaneko,a Ryoji Masui,b Kojiro Ake,b
Seiki Kuramitsu,b Minoru Yamaguchi,c Hiroki Kuyama,c Eiji Ando,c Shigemi Norioka,d Takashi Nakazawa,e
Susumu Tsunasawa,c Hitoshi Yamamotoa and Norikazu Ueyama*a
Received 18th July 2006, Accepted 17th January 2007
First published as an Advance Article on the web 2nd March 2007
DOI: 10.1039/b610284k
The use of a bis(terpyridine)ruthenium(II) complex for peptide labeling (SRuT–CO labeling)
supplied high intensity peaks in mass spectrometry (MS) analysis that overcame the contribution
of protonation or sodiated adduction to peptides. SRuT–CO-labeled insulin A- and B-chains were
detected simultaneously in comparable peak abundance by matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry (MALDI-TOF-MS). The mass spectra of
chymotryptic peptide fragments of SRuT–CO-labeled insulin also simultaneously indicated both
N-terminal fragment ions, and amino acid sequences were determined easily by matrix-assisted
laser desorption/ionization post-source-decay (MALDI-PSD). The sensitivity of detecting
SRuT–CO-labeled peptide fragment ions was not dependent on the length or the sequences of
the peptides. The SRuT–CO labeling method was applied to tryptic myoglobin fragments. The
method indicated that each fragment ion is detected nearly equal in abundance and enabled the
desired fragment ions to be distinguished from matrix clusters or their in-source fragments in
lower mass regions. The desired fragment ions can be found in the mass region higher than 670.70
(= SRuT–CO). This method provided a high sequence coverage (96%) by peptide mass
fingerprinting (PMF). Application of this method to a protein mixture (myoglobin, lysozyme and
ubiquitin) successfully achieved high sequence-coverage characterization (.90%) of these proteins
simultaneously.
Introduction
Tandem time-of-flight mass spectrometry (TOF-MS) is a
powerful technique for the amino acid sequencing of
proteolytic peptides. Peptide mass fingerprinting (PMF) and
peptide sequence tagging (PST) are effective methods used in
protein sequencing.1–6 PMF was developed by some workers in
1993.7 In short, an unknown protein of interest is cleaved into
peptides by a protease such as trypsin. The proteolytic peptides
are measured by matrix-assisted laser desorption/ionization
mass spectrometry (MALDI-MS) or electrospray ionization
mass spectrometry (ESI-MS). These masses are compared with
the masses of the peptides which code for the genome. PST was
developed in the mid 1990s.2,8 PST employs MS/MS (e.g.
collision-induced dissociation; CID) data produced by the
tandem MS method and consists of short strings of amino
acid differences deduced from the fragment spectrum.
Matrix-assisted laser desorption/ionization post-source-decay
(MALDI-PSD) also indicates fragment ion types similar to
those observed under high energy CID conditions.9–11 Using
a combination of these MS analyses and genome database
searching, protein sequencing is automated. However, some
target peptide ions could not be detected because of low
ionization efficiency caused by the acidic side chain in a
positive mode.12 Therefore, the above methods sometimes lead
to ambiguous protein identification.13–15 To reduce ambiguity,
additional information reflecting the primary sequence of a
target protein is required, namely improvement of the PMF
sequence coverage.
Charged derivatization of peptides has been reported to
improve the sensitivity of MS analysis for the desired fragment
ions.16–20 The N-terminal sulfonation of peptides reduces the
intensity of N-terminal fragment ions and enhances the relative
intensity of y-series ions (C-terminal fragment ions) in MS/MS
analysis.18–20 However, some of these methods give a more
complicated spectrum by MS analysis than that without such
a modification. This problem is caused by in-source frag-
mentation of the derivatized peptides, as the derived moiety is
cleaved easily in MS analysis.14
We have demonstrated the amino acid sequencing of
bovine ubiquitin through the use of a chemically inert
bis(terpyridine)ruthenium(II) complex (SRuT–COONSu,
Fig. 1) as an N-terminal-labeling reagent in MALDI-PSD.21
The SRuT–CO moiety is thermodynamically, chemically, and
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photochemically stable. The cationic character causes a high
ionization efficiency in MS analysis. The SRuT moiety has an
intense absorption (e # 5 6 104 M21 cm21) near to the N2
laser frequency (337 nm) in MALDI-TOF-MS. The laser beam
probably excites directly the ligand and/or the metal center and
brings about effective ionization even without the assistance of
any matrix. This excitation occurs partially in MALDI-TOF-
MS measurements and causes photochemical reduction, giving
formal ruthenium(I) species. In MALDI-TOF-MS spectra, this
divalent cationic reagent gives mainly singly-charged ions
including both deprotonated SRuIIT–CO-labeled and SRuIT–
CO-labeled fragments. The SRuIIT/SRuIT ratio is usually
found to be approximately 1 : 1 in various measurements, as
mentioned in a previous paper.21 This phenomenon is
characteristic of MALDI and such a reduction has not been
found in ESI-MS. In both MALDI- and ESI-MS analyses,
the SRuT–CO-labeled peptides were detected with high
sensitivity.22 The PSD or collision-induced decay analysis of
SRuT–CO-labeled fragments enabled easy amino acid sequen-
cing. The detection limit was approximately 10 fmol, which is
sufficient for the analysis of each visible spot in two-
dimensional electrophoresis separation, whereas detection by
gel staining requires at least 100 fmol.23 Application of this
method to PMF should improve the sequence coverage.
In this study, we describe the simultaneous detection of
proteolytic peptides as a technique for improving the sequence
coverage of the PMF method. Initially, bovine insulin was
reacted with the SRuT–CO labeling reagent. Bovine insulin is
composed of two peptide chains (A- and B-chains), and each
peptide shows an individual isoelectric point (pI). The SRuT–
CO-labeled insulin was measured by MALDI-TOF-MS to
examine the effect of the peptide chains’ pI on the ionization
process during MS analysis. The chymotryptic peptides of
SRuT–CO-labeled insulin were also measured by MALDI-
TOF-MS to investigate the dependence on the length of the
peptides. The technique of PMF analysis using SRuT–CO
labeling was applied to tryptic myoglobin fragments and
tryptic fragments of a protein mixture (myoglobin, lysozyme
and ubiquitin).
Experimental
Materials
[(tpy)Ru(tpyC6H4COONSu)]Cl2 ([SRuT–COONSu]Cl2) was
synthesized by a procedure similar to that reported in a pre-
vious study.21 Bovine insulin, myoglobin (from horse heart),
ubiquitin (from bovine red blood cells), lysozyme (from
chicken egg white) and a-chymotrypsin were purchased from
Sigma (St Louis, USA). Trypsin Gold was purchased from
Promega (Madison, USA). All other chemicals were purchased
from Nacalai Tesque (Kyoto, Japan).
Reduction and alkylation
Insulin (1.1 mg, 200 nmol) was dissolved in 600 mL of
0.5 mol dm23 Tris buffer (0.5 mol dm23 Tris HCl, 7 mol dm23
guanidine hydrochloride, and 10 mmol dm23 EDTA).
Dithiothreitol (3.70 mg, 24 mmol) was added to the solution.
The solution was incubated at 56 uC for 50 min. Iodoacet-
amide (8.8 mg, 48 mmol) was then added, and the mixture was
shaken for 1 h at room temperature in the dark. The excess
reagents were removed using the Float-A-Lyzer dialysis tube
[molecular weight cut off (MWCO) 1000]. The reaction
products were characterized by MALDI-TOF-MS.
Guanidination
The guanidination of e-amino groups was performed following
Beardsley and Reilly’s method24 with some modifications. The
solution of O-methylisourea (21 mg, 81 mmol) in 7 mol dm23
NH3 aq. (0.1 mL) was added to the carbamidomethylated
insulin solution and incubated for 10 min at pH 10.6 and 65 uC.
After incubation, 300 mL of 10% trifluoroacetic acid (TFA)
was added to the solution in an ice bath. The excess reagents
were removed using the Float-A-Lyzer dialysis tube (MWCO
1000). The solution was concentrated to 60 mL in a vacuum
centrifuge and desalted on a ZipTipC18 pipette (Millipore,
Bedford, USA) for the MALDI-TOF-MS measurement.
SRuT–CO labeling
[SRuT–COONSu]Cl2 (0.13 mg, 150 nmol) and triethylamine
(1.5 mL) were added to the guanidinated insulin solution
(600 mL, ca. 40 nmol). The mixture was incubated at 40 uC for
24 h. A 20 mL portion of the solution was desalted on a
ZipTipC18 pipette for the MALDI-TOF-MS analysis.
Chymotryptic digestion
The solution was concentrated to 50 mL under reduced
pressure. After cooling to room temperature, 300 mL of
50 mmol dm23 NaHCO3 buffer and 10 mL of chymotrypsin
aqueous solution containing 11 mg of chymotrypsin were
added. The mixture was incubated at 37 uC overnight. A 20 mL
portion of the solution was purified using a ZipTipC18 pipette
for MALDI-TOF-MS analysis.
In-gel digestion of myoglobin
Myoglobin was resolved by one-dimensional sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Each
observed spot was cut into small pieces and collected in a
microtube. The samples were reduced and alkylated in a
similar way as described above for the in-solution method.
The reactant was digested by trypsin, as described for the
chymotryptic digestion. The tryptic peptides were guanidi-
nated and SRuT–CO-labeled by a method similar to that
mentioned in the previous section. A 20 mL portion of the
Fig. 1 Active ester of bis(terpyridine)ruthenium(II) complex.
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solution was purified using a ZipTipC18 pipette for MALDI-
TOF-MS analysis.
Preparation of SRuT–CO-labeled peptides for a protein mixture
One mL of each of myoglobin, lysozyme and ubiquitin
aqueous solution (1 mmol dm23) were mixed. The mixture
was reduced, alkylated, digested by trypsin, guanidinated, and
SRuT–CO-labeled, successively, by a similar as mentioned
above. A 20 mL portion of the solution was purified using a
ZipTipC18 pipette for MALDI-TOF-MS analysis.
Physical measurements
Sample preparation. a-Cyano-4-hydroxycinnamic acid
(CHCA) or 2,5-dihydroxybenzoic acid (DHB) was saturated
in a 50% acetonitrile aqueous solution containing 0.1% TFA.
The saturated solution was diluted 20 times to produce a
matrix solution. First, 1 mL of the matrix solution was applied
to the sample plate. This was followed by the addition of
1 mL of sample solution and was allowed to dry under ambient
conditions.
MALDI-TOF/TOF-MS. MALDI-TOF/TOF-MS spectra
were recorded in a positive mode on a Bruker Ultraflex
TOF/TOF mass spectrometer controlled by the Flexcontrol 2.2
software package. External calibration of MALDI mass
spectra was carried out using singly-charged monoisotopic
peaks of a mixture of human angiotensin II (m/z 1046.54),
angiotensin I (m/z 1296.68), bombesin (m/z 1619.82), and
adrenocorticotropic hormone (m/z 2093.08).
MALDI-TOF-MS. MALDI-TOF-MS and PSD spectra
were recorded in a positive-ion mode on Shimadzu/Kratos
AXIMA-CFR in a reflectron mode controlled by the
KOMPACT 2.3.5 software package. External calibration of
MALDI mass spectra was carried out using the monoisotopic
mass of human angiotensin II (m/z 1046.54) or bovine insulin
(m/z 5734.56). Metastable ions that were generated by laser-
induced decomposition of the selected precursor ions were
analyzed. Precursor ions were accelerated to 20 kV and
selected in a timed ion gate.
Results and discussions
Simultaneous detection of SRuT–CO-labeled insulin
Initially, SRuT–CO labeling of bovine insulin was carried out
according to the procedure shown in Fig. 2. The insulin
A-chain has two acidic and no basic amino acid residues. The
insulin B-chain has two acidic and four basic amino acid
residues, including one Lys residue. The pI of the A-chain is
lower than that of the B-chain. In addition, a positive charge
was introduced to the B-chain by guanidination. Therefore,
the insulin B-chain is detected easily in a positive-ion mode.
Guanidinated insulin and SRuT–CO-labeled insulin were
measured by MALDI-TOF/TOF-MS to estimate the effect of
the SRuT–CO moiety (Fig. 3). In the case of guanidinated
insulin, the fragment ions of the A-chain (+ H+: m/z 2566.3,
calcd. 2566.2; + Na+: m/z 2588.2, calcd. 2588.0) were observed
with a lower intensity than that of the B-chain (+ H+: m/z
3511.9, calcd. 3511.7) – a result of the restricted protonation of
the acidic residues [Fig. 3(a)].
On the other hand, the analysis of SRuT–CO-labeled insulin
indicated both fragment ions of the SRuT–CO-labeled A- (m/z
3237.2, calcd. 3236.2) and B-chains (m/z 4240.1, calcd. 4240.8)
in comparable peak abundances, as shown in Fig. 3(b). The
similar intensity is probably caused by similar physicochemical
properties after derivatization. The large SRuT–CO moiety
results in there being less of a dependency of the intensity on
the bonded peptides in MS analysis. Moreover, this labeling
enhances the relative peak intensity. The SRuT–CO-labeled
insulin gives an intense peak using only low pmol quantities of
sample in Fig. 3(b) where the amount of labeled sample is less
than one-hundredth of the unlabeled one (labeled sample:
1.5 pmol, unlabeled sample: 200 pmol). To compare directly
the increase of absolute intensity after derivatization, an
equimolar mixture of labeled and unlabeled angiotensin II was
analyzed by MALDI-TOF-MS (Fig. 4). Generally, a broad
isotope distribution (multi-isotope) reduces the peak intensity
in MS analysis. However, in this case, the intensity of the
SRuT–CO-labeled fragment was observed to be about three
Fig. 2 Procedure for N-terminal SRuT–CO labeling of insulin: (1) all
cystine residues are reduced by dithiothreitol and S-alkylated using
iodoacetamide; (2) all e-amino groups of lysine residues are
guanidinated with O-methylisourea; (3) N-terminal amino acid
residues are selectively labeled with the SRuT–CO labeling reagent;
(4) derived proteins are digested by a-chymotrypsin.
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times that of the unlabeled one, though the isotope distribu-
tion lowers the peak height by about 30% (Fig. 4). These
results suggest that the ionization efficiency of the SRuT
moiety surpasses the contribution of the protonation or
sodiated adduction to peptides. The intensity of the individual
isotopic form is reduced by spreading the abundance across
several ions, but this also increases confidence in the assign-
ment. In Fig. 3(b), the sobtained fragment peaks show
characteristic isotope distribution patterns that are in agree-
ment with the calculated one (Fig. 5).{ The SRuT–CO labeling
method allowed simultaneous detection of the fragment ions
of the insulin A- and B-chains despite the contribution of
protonation or sodiated adduction. In addition, this method
enabled easy distinction of the desired peaks by their
characteristic isotope distribution pattern.
The chymotryptic peptide fragments of SRuT–CO-labeled
insulin were also examined by MALDI-TOF-MS (Fig. 6).
Two SRuT–CO-labeled fragment peaks appeared at m/z 958.07
(fA) and m/z 933.40 (fB) with approximately the same peak
abundance as observed for the original SRuT–CO-labeled
chains. Another peak was caused by the [SRuT–COOH +
2DHB 2 H2O]
+ ion. These results suggest that the SRuT–CO
Fig. 4 MALDI-TOF-MS spectrum of SRuT–CO-labeled and
unlabeled angiotensin II.
Fig. 5 Expanded spectrum (upper) and its calculated spectrum
(lower) of the peak at (a) m/z 3237.2, and (b) m/z 4240.1 in Fig. 3(b).
{ In this calculation, half of the ruthenium ions were assumed to be
reduced to RuI.21
Fig. 6 MALDI-TOF-MS spectrum of SRuT–CO-labeled insulin
digested by a-chymotrypsin.
Fig. 3 MALDI-TOF/TOF-MS spectra of (a) 200 pmol of guanidi-
nated insulin, and (b) 1.5 pmol SRuT–CO-labeled insulin.
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labeling gives uniform intensity for various peptides with
individual sequence and length. The observed SRuT–CO-
labeled fragment peaks were analyzed by MALDI-PSD to
determine the amino acid sequences (Fig. 7). Each spectrum
indicates predominantly an and dn fragment ions because
the SRuT–CO-labeled peptides are cleaved easily at the
Ca-carbonyl and Cb–Cc bonds.
21,22 These fragment ions
allow accurate determination of the amino acid sequences of
the desired fragment ions by reading successively from
the N-terminal amino acid residue to the C-terminus. The
SRuT–CO labeling method enabled us to detect simulta-
neously all SRuT–CO-labeled fragment ions and to determine
their sequences.
PMF analysis of tryptic peptides of myoglobin using a SRuT–
CO labeling reagent
The procedure of PMF analysis using SRuT–CO labeling is
shown in Fig. 8. Myoglobin has 20 acidic and 31 basic amino
acid residues (Chart 1). Myoglobin produces 20 fragments by
tryptic digestion, and these fragments were guanidinated (see
Table S1,{ homoarginine residues are represented by K*).
After step 3 in Fig. 8, guanidinated peptides were analyzed by
MALDI-TOF-MS [Fig. 9(a)]. Fig. 9(b) shows the MALDI-
TOF-MS spectrum of the self-digested peptides of trypsin. In
Fig. 9, these spectra are clearly different from one another. The
self-digested fragments of trypsin were not observed in
Fig. 9(a). Therefore, the influence of self-digested peptides of
trypsin in Fig. 9(a) can be disregarded. In Fig. 9(a), most
fragments arise from the protonation of tryptic fragments, and
others were observed to be sodiated adduct ions (Na+ or K+).
In the lower mass range (,m/z 600), the spectrum was
complicated because of ions from the matrix (DHB) cluster
and its derivatives. In this range, the peaks (f16, f18, and f19),
which can be distinguished clearly from the DHB cluster ions,
were assigned. The observed fragment ions (monoisotopic
mass) with the calculated mass numbers are listed in Table S2.{
Fragments f9, f12, and f13 were not detected. These fragments
have comparatively high acidity, for which the pI values are
4.53, 5.84 and 4.00, respectively (Table S1{). Therefore, the
peak intensity of these fragment ions is relatively low in a
positive-ion mode. Other acidic fragments (e.g. f2: m/z =
1859.0, pI = 4.37; f3: m/z = 1607.8 pI = 4.65; f6: m/z = 1314.5,
Fig. 7 MALDI-PSD spectra of the fragment ions (a) fA at m/z 958.07,
and (b) fB at m/z 933.40.
Fig. 8 SRuT–CO labeling procedure of enzymatic peptides: (1) all
cystine residues are reduced by dithiothreitol and S-alkylated using
iodoacetamide; (2) derived proteins are digested by trypsin; (3) all
e-amino groups of lysine residues are guanidinated with O-methyl-
isourea; (4) peptides are labeled with SRuT–CO labeling reagent; (5)
derived peptides are desalted on ZipTipC18.
Chart 1 Amino acid sequence of myoglobin. The shading indicates
indicate basic amino acid residues. The underlining indicates acidic
amino acid residues.
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pI = 5.40) were also obtained as very minor peaks. On the
other hand, basic fragments f5 (m/z = 1405.5, pI = 8.76) and f7
(m/z = 1170.7, pI = 9.18) were observed as relatively intense
peaks in Fig. 9(a). In this case, the sequence coverage was 75%.
After SRuT–CO labeling (Fig. 8, step 4), the labeled peptides
were desalted using a ZipTipC18 pipette. These peptides were
analyzed by MALDI-TOF-MS (Fig. 10). All fragment ions are
singly-charged as found in the previous measurements.21,22
The observed fragment ions with their calculated mass
numbers are listed in Table S3.{ Some fragment ions appeared
in the form with an elimination of the C-terminal arginine
or homoarginine residue. By use of the SRuT–CO labeling
method (Fig. 10 and Table S3{), all fragment ions were
observed as more being intense peaks than the unlabeled
peptide fragments [Fig. 9(b)]. In addition, acidic fragments f9,
f12, f13 and lower mass fragments f15, f17, f20 were also detected,
which were not observed without the labeling (Fig. 9). High
sequence coverage (96%) was achieved by the SRuT–CO
labeling method. This method shifted the desired fragment
ions to a higher mass region (MW . 700), in which
background is low in MALDI-TOF-MS and hence the method
gave better spectra. Therefore, the method enables desired
fragment ions to be distinguished from undesired ones, such as
matrix clusters or self-digested fragments of protease, and
improves the sequence coverage of the proteolytic peptides.
Application of PMF analysis using the SRuT–CO labeling
reagent on a protein mixture
The analysis method was applied to a protein mixture
(myoglobin, lysozyme and ubiquitin). The SRuT–CO-labeled
fragments were desalted using a ZipTipC18 pipette and
analyzed by MALDI-TOF-MS (Fig. 11). The predicted
fragments with their calculated mass numbers are summarized
in Table S1 and S4.{ The observed fragments are listed in
Table S5{ with their calculated mass numbers. In this case,
some fragment ions also appeared in the form with an
elimination of the C-terminal arginine or homoarginine
residue. In addition, some fragments were caused by the
cleavage of the guanidyl group or by dehydration. The SRuT–
CO-labeling method provided the high sequence-coverage
characterization of the three proteins simultaneously (myoglo-
bin: 95%; lysozyme: 97%; ubiquitin: 91%).
Conclusions
The introduction of SRuT–CO moieties to peptides achieved
high sequence coverage in PMF analysis. The SRuT–CO-
labeled insulin A- and B-chains were observed in comparable
peak abundance in the MS spectra, despite the fact that the
A-chain exhibits weak intensity without the labeling.
Application of this labeling method to PMF improved the
sequence coverage. This method also provided high sequence-
coverage characterization simultaneously for the individual
proteins within a protein mixture. Furthermore, this method
brought easy amino acid sequencing into MS/MS analysis.
Therefore, this labeling method is applicable for PST and is
easily adaptable to Mascot searching, as all fragments shift
only by the same molecular weight. The use of our analytical
method for protein identification should allow accurate and
rapid determination.
Fig. 9 MALDI-TOF-MS spectra of (a) tryptic peptides of myoglo-
bin, and (b) self-digested peptides of trypsin.
Fig. 10 MALDI-TOF-MS spectrum of SRuT–CO-labeled peptides of tryptic myoglobin using a DHB matrix. Peaks marked by asterisks
correspond to DHB clusters and their derivatives. Insets are enlarged spectra around m/z 1493.7, 2427.4 and 2597.2.
This journal is  The Royal Society of Chemistry 2007 Analyst, 2007, 132, 358–364 | 363
Acknowledgements
One of the authors (A. I.) expresses his special thanks for
the 21st Century Center of Excellence (21COE) program
‘‘Creation of Integrated EcoChemistry of Osaka University’’.
This work was supported in part by Japan’s National Project
on Protein Structural and Function Analyses and by a
Grant-in-Aid for Scientific Research (A) (No. 15201043)
from the Ministry of Education, Culture, Sports, Science,
and Technology, Japan.
References
1 J. R. Yates, III, J. Mass Spectrom., 1998, 33, 1–19.
2 M. Mann and M. Wilm, Anal. Chem., 1994, 66, 4390–4399.
3 O. N. Jensen, A. V. Podtelejnikov and M. Mann, Anal. Chem.,
1997, 69, 4741–4750.
4 P. A. Demirev, J. Ramirez and C. Fenselau, Anal. Chem., 2001, 73,
5725–5731.
5 B. Warsheid and C. Fenselau, Anal. Chem., 2003, 75,
5618–5627.
6 Y. An, Z. Fu and C. Fenselau, J. Mass Spectrom. Soc. Jpn., 2005,
53, 1–6.
7 W. J. Henzel, T. M. Billeci, T. M. Stults, S. C. Wong, C. Grimley
and C. Watanabe, Proc. Natl. Acad. Sci. U. S. A., 1993, 90,
5011–5015; P. James, M. Quadroni, E. Carafoli and G. Gonnet,
Biochem. Biophys. Res. Commun., 1993, 195, 58–64; M. Mann,
P. Hojrup and P. Roepstorff, Biol. Mass Spectrom., 1993, 22,
338–345; D. J. C. Pappin, P. Hojrup and A. J. Bleasby, Curr. Biol.,
1993, 3, 327–332; J. R. Yates, III, S. Speicher, P. R. Griffin and
T. Hunkapiller, Anal. Biochem., 1993, 214, 397–408.
8 E. Mortz, P. B. O’Connor, P. Roepstroff, N. L. Kelleher,
T. D. Wood, F. W. McLafferty and M. Mann, Proc. Natl. Acad.
Sci. U. S. A., 1996, 93, 8264–8267; A. Shevchenko, O. N. Jensen,
A. V. Podtelejnikov, F. Sagliocco, M. Wilm, O. Vorm,
P. Mortensen, A. Shevchenko, H. Boucherie and M. Mann,
Proc. Natl. Acad. Sci. U. S. A., 1996, 93, 14 440–14 445.
9 R. Kaufmann, B. Spengler and F. Lutzenkirchen, Rapid Commun.
Mass Spectrom., 1993, 7, 902–910.
10 K. Biemann, Annu. Rev. Biochem., 1992, 61, 977–1010.
11 D. Fabris, M. M. Vestling, M. M. Cordero, V. M. Doroshenko,
R. J. Cotter and C. Fenselau, Rapid Commun. Mass Spectrom.,
1995, 9, 1051–1055.
12 N. P. Ewing and C. J. Cassady, J. Am. Soc. Mass Spectrom., 2001,
12, 105–116; A. Beck, M. Deeg, K. Moeschel, E. K. Schmidt,
E. D. Schleicher, W. Voelter, H. U. Ha¨ring and R. Lehmann,
Rapid Commun. Mass Spectrom., 2001, 15, 2324–2333.
13 T. Keough, M. P. Lacey and R. S. Youngquist, Rapid Commun.
Mass Spectrom., 2002, 16, 1003–1015.
14 U. Hellman and R. Bhikhabhai, Rapid Commun. Mass Spectrom.,
2002, 16, 1851–1859.
15 P. Chen, S. Nie, W. Mi, X.-C. Wang and S.-P. Liang, Rapid
Commun. Mass Spectrom., 2004, 18, 191–198.
16 J. Zaia and K. Biemann, J. Am. Soc. Mass Spectrom., 1995, 6,
428–436.
17 K. D. W. Roth, Z.-H. Huang, N. Sadagopan and J. T. Watson,
Mass Spectrom. Rev., 1998, 17, 255–274.
18 T. Keough, R. S. Youngquist and M. P. Lacey, Anal. Chem., 2003,
75, 156A–165A.
19 T. Keough, R. S. Youngquist and M. P. Lacey, Proc. Natl. Acad.
Sci. U. S. A., 1999, 96, 7131–7136.
20 D. Wang, S. R. Kalb and R. J. Cotter, Rapid Commun. Mass
Spectrom., 2004, 18, 96–102.
21 T. Okamura, T. Iwamura, A. Ito, M. Kaneko, M. Yamaguchi,
H. Yamamoto, N. Ueyama, H. Kuyama, E. Ando, S. Norioka,
T. Nakazawa, R. Masui and S. Kuramitsu, Chem. Lett., 2005, 34,
332–333.
22 A. Ito, T. Okamura, H. Yamamoto, N. Ueyama, K. Ake, R. Masui,
S. Kuramitsu and S. Tsunasawa, Anal. Chem., 2005, 77,
6618–6624.
23 H. Katayama, K. Satoh, M. Takeuchi, M. Deguchi-Tawarada,
Y. Oda and T. Nagasu, Rapid Commun. Mass Spectrom., 2003, 17,
1071–1078.
24 R. L. Beardsley and J. P. Reilly, Anal. Chem., 2002, 74, 1884–1890.
Fig. 11 MALDI-TOF-MS spectrum of SRuT–CO-labeled tryptic fragments of protein mixture. Insets are enlarged spectra around m/z 1506.6,
1983.2 and 3219.9.
364 | Analyst, 2007, 132, 358–364 This journal is  The Royal Society of Chemistry 2007
